Investigation of liver-targeted peripheral Focused Ultrasound Stimulation (pFUS) and its effect on glucose homeostasis and insulin resistance in Type 2 Diabetes Mellitus: a proof of concept, Phase 1 Trial.

We report post-pFUS trends in several outcomes that were consistent with previous pre-clinical findings. Fasting insulin was lowered, resulting in a reduction of HOMA-IR scores (p-value 0.01; corrected Wilcoxon Signed-Rank Test). Additional safety and exploratory markers demonstrated no device-related adverse impact of pFUS. Our findings demonstrate that pFUS represents a promising new treatment modality that could be used as a non-pharmaceutical adjunct or even alternative to current drug treatments in diabetes.